TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19247233

Group type: EXPERIMENTAL
Intervention: Polyurethane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrocolloid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrogel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard plasters
Number of subjects: 10
Study: 17222829

Group type: EXPERIMENTAL
Intervention: Unopposed conjugated estrogen therapy (0.625 mg/d)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/d)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 15703460

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 50 mg intramuscularly twice weekly combined with erythropoietin (EPO) 1,000 U three times weekly
Number of subjects: 32

Group type: COMPARATOR
Intervention: Erythropoietin (EPO) 1,000 U three times weekly
Number of subjects: 32
Study: 12127032

Group type: EXPERIMENTAL
Intervention: Continuous morphine (CM) at 10 microg/kg/h intravenous infusion
Number of subjects: 181

Group type: COMPARATOR
Intervention: Intermittent morphine (IM) at 30 microg/kg every 3 hours
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Continuous morphine (CM)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Intermittent morphine (IM)
Number of subjects: 181
Study: 9612677

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization (TVP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 150
Study: 7753258

Group type: EXPERIMENTAL
Intervention: Potassium citrate (0.5 mmol/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium citrate (0.5 mmol/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time control group (no ion ingestion)
Number of subjects: 0
Study: 31665733

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 7437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7437
Study: 28854065

Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg twice daily on days 1 to 5) with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8 mg on days 2 to 4)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Placebo with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8 mg on days 2 to 4)
Number of subjects: 638
Study: 27209526

Group type: EXPERIMENTAL
Intervention: Thinking Skills Work (TSW)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Enhanced Vocational Rehabilitation (E-VR)
Number of subjects: 54
Study: 24606087

Group type: EXPERIMENTAL
Intervention: Low-dose rhIGF-I/rhIGFBP-3 (30 mg/d)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-dose rhIGF-I/rhIGFBP-3 (60 mg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 21987363

Group type: EXPERIMENTAL
Intervention: Suture anchor fixation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Screw fixation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pull-out suture fixation
Number of subjects: 14
Study: 19805678

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 802

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 802
Study: 16765234

Group type: EXPERIMENTAL
Intervention: Coronary artery revascularization
Number of subjects: 307

Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: CLI
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: IC
Number of subjects: 307
Study: 15628646

Group type: EXPERIMENTAL
Intervention: In-patient psychotherapeutic treatment with accompanying children
Number of subjects: 29

Group type: COMPARATOR
Intervention: In-patient psychotherapeutic treatment without accompanying children
Number of subjects: 29
Study: 11164146

Group type: EXPERIMENTAL
Intervention: Microwave treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Terazosin treatment
Number of subjects: 52
Study: 9230157

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 81 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Regular aspirin 81 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 325 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Regular aspirin 325 mg
Number of subjects: 40
Study: 8109281

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) in actively treated group A (12 patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group B (10 patients, received implantation after the study period)
Number of subjects: 24
Study: 3630582

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Meperidine 0.5 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (Midazolam or Diazepam)
Number of subjects: 8
Study: 29050650

Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (DSF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (standard supplement)
Number of subjects: 20
Study: 27982267

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 25262253

Group type: EXPERIMENTAL
Intervention: Indapamide (1.5 mg Slow Release (SR)/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg/d)
Number of subjects: 56
Study: 24041245

Group type: EXPERIMENTAL
Intervention: Cogmed (adaptive working memory training)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (non-adaptive version of Cogmed)
Number of subjects: 126
Study: 20810085

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 19494558

Group type: EXPERIMENTAL
Intervention: Nutritional therapy, details not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surfactant replacement, 'kinder gentler' modes of ventilation, prenatal corticosteroids
Number of subjects: 0
Study: 15904750

Group type: COMPARATOR
Intervention: Augmented intervention (e-mail reminder with provider prompts, patient education material, and clinical nurse specialist outreach)
Number of subjects: 673

Group type: COMPARATOR
Intervention: Basic intervention (one-time e-mail reminder highlighting six pain-specific clinical recommendations)
Number of subjects: 673

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 673
Study: 12456381

Group type: EXPERIMENTAL
Intervention: Mannitol challenge
Number of subjects: 50

Group type: COMPARATOR
Intervention: Eucapnic voluntary hyperpnea (EVH) challenge
Number of subjects: 50
Study: 10480154

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Calcium Carbonate (CaCO3)
Number of subjects: 16
Study: 8630574

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 750 micrograms/d
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 1,500 micrograms/d
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 21
Study: 1672493

Group type: EXPERIMENTAL
Intervention: Intranasal cromolyn sodium, 1 spray in each nostril QID for 4 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Oral terfenadine, 60 mg BID for 4 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Intranasal cromolyn sodium
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Oral terfenadine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cromolyn sodium and terfenadine
Number of subjects: 79
Study: 7037487

Group type: EXPERIMENTAL
Intervention: Metergoline (10 mg daily for two days plus a 4 mg dose 1 hour before the post-treatment test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metergoline
Number of subjects: 0
Study: 31522355

Group type: EXPERIMENTAL
Intervention: Semi-supervised co-adaptive BCI
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supervised co-adaptive BCI
Number of subjects: 20
Study: 30361325

Group type: EXPERIMENTAL
Intervention: Sparsentan (200, 400, or 800 mg/d)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sparsentan (400 and 800 mg/d)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sparsentan
Number of subjects: 96

Group type: COMPARATOR
Intervention: Irbesartan (300 mg/d)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sparsentan and Irbesartan
Number of subjects: 96
Study: 27646499

Group type: EXPERIMENTAL
Intervention: Pictorial warnings on cigarette packs
Number of subjects: 112

Group type: COMPARATOR
Intervention: Text-only warnings on cigarette packs
Number of subjects: 112
Study: 24811201

Group type: EXPERIMENTAL
Intervention: Nicotine patch (n=182)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo patch (n=180)
Number of subjects: 257
Study: 22732966

Group type: EXPERIMENTAL
Intervention: Nutritional guidance about diet and its relationship with disease, sources of nutrients, and reduction of dietary sodium and fats
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study: 21062541

Group type: EXPERIMENTAL
Intervention: Psychologically informed sessions based on cognitive-behavioural therapy or person-centred counselling principles
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Use of the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Health visitor's support
Number of subjects: 30
Study: 18430980

Group type: EXPERIMENTAL
Intervention: Neuropsychological rehabilitation (NR) program in group NR (N=5)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Individualized neuropsychological rehabilitation (NR) in individualized NR group (N=6)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Neuropsychological rehabilitation (NR) at home under supervision of a relative or caregiver (N=5)
Number of subjects: 16
Study: 15157043

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (G2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care (G1)
Number of subjects: 27
Study: 11680947

Group type: EXPERIMENTAL
Intervention: Paracervical lidocaine block
Number of subjects: 103

Group type: COMPARATOR
Intervention: Vaginal application of Emla
Number of subjects: 103
Study: 9043838

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 7936945

Group type: EXPERIMENTAL
Intervention: Positive music
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Negative music
Number of subjects: 14

Group type: COMPARATOR
Intervention: White noise
Number of subjects: 14
Study: 2851181

Group type: EXPERIMENTAL
Intervention: Cisplatin 120 mg/m2 every 4 weeks and vindesine 3 mg/m2 weekly
Number of subjects: 201

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cisplatin/vindesine (chemotherapy)
Number of subjects: 201

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 201
Study: 31993658

Group type: EXPERIMENTAL
Intervention: Distress Tolerance Treatment (DT-W)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Smoking Health Education (HE)
Number of subjects: 69
Study: 29471677

Group type: EXPERIMENTAL
Intervention: Emotion-focused coping
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Problem-focused coping
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Greater family support
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Higher community support
Number of subjects: 288
Study: 27030088

Group type: EXPERIMENTAL
Intervention: Liothyronine 15 μg for two weeks, then 30-45 μg for four weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liothyronine 30-45 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liothyronine therapy
Number of subjects: 0
Study: 24913003

Group type: EXPERIMENTAL
Intervention: C-TraIn (multicomponent transitional care improvement program)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382
Study: 22646973

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Airtraq(®) laryngoscope
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Storz DCI(®) laryngoscope
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gyrus Infant Bullard(®) laryngoscope
Number of subjects: 30
Study: 20336804

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 46
Study: 18587249

Group type: EXPERIMENTAL
Intervention: Catheter‐assisted TURP
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional TURP
Number of subjects: 61
Study: 15961567

Group type: EXPERIMENTAL
Intervention: Early headgear (HG) treatment initiated immediately
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group with minor interceptive procedures
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups underwent orthodontic therapy including fixed appliances and possible extractions when necessary
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Early headgear (HG) treatment
Number of subjects: 68
Study: 11785738

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10233492

Group type: EXPERIMENTAL
Intervention: L-arginine (5 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9119427

Group type: EXPERIMENTAL
Intervention: Antenatal care programme (early registration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1760424

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NEA) 1 mg + ethinyl oestradiol (EE) 50 micrograms
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 250 micrograms + EE 50 micrograms
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: LNG 250 micrograms + EE 30 micrograms
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: LNG 150 micrograms + EE 30 micrograms
Number of subjects: 622

Group type: COMPARATOR
Intervention: Control group (155 women not receiving OC)
Number of subjects: 622
Study: 6802085

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 109

Group type: COMPARATOR
Intervention: Ampicillin plus cloxacillin
Number of subjects: 109
Study: 30981629

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1000 mg, n = 86)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Oral iron (II) fumarate (100 tablets of 100 mg [10 per week], n = 90)
Number of subjects: 176
Study: 31292107

Group type: EXPERIMENTAL
Intervention: 10% BWSTT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20% BWSTT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unsupported TT (control group)
Number of subjects: 30
Study: 28335000

Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo feedback training (sham)
Number of subjects: 25
Study: 26521922

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) for 2 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Venturi mask oxygen for 2 hours
Number of subjects: 100
Study: 24123319

Group type: EXPERIMENTAL
Intervention: ASL MRI at 1.5T
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: ASL MRI at 3T
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: ASL MRI in group a (good/moderate function)
Number of subjects: 98

Group type: COMPARATOR
Intervention: ASL MRI in group b (poor function)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Correlation of ASL perfusion with eGFR
Number of subjects: 98
Study: 23095628

Group type: EXPERIMENTAL
Intervention: Stapler group
Number of subjects: 337

Group type: COMPARATOR
Intervention: Hand suture group
Number of subjects: 337
Study: 19172098

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg) twice a week for 4 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (10 patients with ED who did not take any treatment)
Number of subjects: 32
Study: 17567687

Group type: EXPERIMENTAL
Intervention: Positive interaction with a peer under stress, referral to medical or management staff if problems do not resolve.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Reporting ideas of DSH.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Active involvement in the care of peers and appropriate referral if the situation deteriorates.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Perception of DSH as a medical problem requiring immediate intervention.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Help seeking behavior regarding DSH.
Number of subjects: 142
Study: 15710092

Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 3,600 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12213867

Group type: EXPERIMENTAL
Intervention: Nateglinide 30 mg
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Nateglinide (all doses)
Number of subjects: 675
Study: 9823014

Group type: EXPERIMENTAL
Intervention: Glucerna (50% fat)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ensure with Fibre (30% fat)
Number of subjects: 32
Study: 7864913

Group type: EXPERIMENTAL
Intervention: Active message designed to encourage giving up smoking
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control message (voice counting numbers)
Number of subjects: 122
Study: 3781675

Group type: EXPERIMENTAL
Intervention: Propranolol, 40 mg t.i.d.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diltiazem, 60 mg t.i.d.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 13
Study: 30445922

Group type: EXPERIMENTAL
Intervention: Nutritional telemonitoring, television messages, and dietary advice by a nurse or a dietician for 6 months
Number of subjects: 215

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215
Study: 29231561

Group type: EXPERIMENTAL
Intervention: Tongdu Rezhen method
Number of subjects: 68

Group type: COMPARATOR
Intervention: Twirling‐reinforcing needling method
Number of subjects: 68
Study: 24237386

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg once daily for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22726914

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral smoking cessation treatment (CBT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Autogenic training (Control Group)
Number of subjects: 103
Study: 20592253

Group type: EXPERIMENTAL
Intervention: BRV 5 mg/day
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: BRV 20 mg/day
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 19099943

Group type: EXPERIMENTAL
Intervention: DK crush technique
Number of subjects: 311

Group type: COMPARATOR
Intervention: Classical crush technique (C)
Number of subjects: 311
Study: 18824852

Group type: EXPERIMENTAL
Intervention: Intermittent pantoprazole infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous pantoprazole infusion
Number of subjects: 0
Study: 15197501

Group type: EXPERIMENTAL
Intervention: Co-registered gated SPECT-CT images
Number of subjects: 23
Study: 11307261

Group type: EXPERIMENTAL
Intervention: Group I (no leakage and slight leakage specimens immersed in methylene blue 2% for 24 h)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group II (water-filled gaps immersed in methylene blue 2% for 24 h)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group III (dry gaps with transport air applied, immersed in methylene blue 2% for 24 h)
Number of subjects: 80
Study: 9091798

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (25 Gy delivered in five fractions in one week) followed by surgery
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Patients treated with curative resection after preoperative irradiation
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Patients treated with curative resection after surgery alone
Number of subjects: 1168
Study: 8458598

Group type: EXPERIMENTAL
Intervention: L-Dopa (300 mg total: 50 mg at 9 am, 100 mg before lunch, 150 mg before dinner)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3752422

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg lormetazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.02 mg/kg flunitrazepam
Number of subjects: 20
Study: 30666823

Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg) plus azathioprine (2 mg/kg/day) and low-dose oral glucocorticoids (≤10 mg/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo plus azathioprine (2 mg/kg/day) and low-dose oral glucocorticoids (≤10 mg/day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 30020423

Group type: EXPERIMENTAL
Intervention: S-ketamine (0.006 mg/kg/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 26401633

Group type: EXPERIMENTAL
Intervention: Buzzy (cooling vibration device)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 70
Study: 25224317

Group type: EXPERIMENTAL
Intervention: Minimally tailored newsletters
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Enhanced tailored newsletters
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Minimally tailored newsletters among those with autonomous communication preference
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Enhanced tailored newsletters among those with autonomous communication preference
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Minimally tailored newsletters among those with directive communication preference
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Enhanced tailored newsletters among those with directive communication preference
Number of subjects: 881